Hamish Aitken-Buck: New Insights Challenge the Role of Histidine Rich Glycoprotein in Thrombosis
Hamish Aitken-Buck, Clinical Research Strategist at Thrombosis Research Institute, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Really pleased to see our latest study now available on medRxiv, the result of a great collaboration between the Thrombosis Research Institute, London and colleagues at Duke and McMaster.
Using data from more than 50,000 participants in the UK Biobank Pharma Proteomics Project, we applied a two-sample Mendelian randomisation approach to investigate whether genetically predicted levels of histidine-rich glycoprotein (HRG) are causally associated with thrombosis risk. Somewhat surprisingly, we found no evidence of an association with either arterial or venous thrombosis.
As often happens in research, the findings raise as many questions as they answer.
- How does the rs9898 variant affect HRG function?
- Why does its relationship with HRG protein levels differ across proteomic platforms?
- And if HRG influences coagulation and thrombogenesis in experimental models, why doesn’t this appear to translate into clinical thrombotic outcomes?
Plenty of new questions to explore.
Many thanks to all the collaborators who made this work possible.”
Title: Histidine-rich glycoprotein is not associated with thrombosis in a UK Biobank Mendelian randomisation analysis
Authors: Yuncheng Duan, Hamish M. Aitken-Buck, Peter MacCallum, Jeffrey I. Weitz, Ajay K. Kakkar, Andrew S. Allen
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 4, 2026, 18:57Connecting Haemophilia Centres, Certifying Treaters, and Improving National Data in Romania – EHC
-
Nov 4, 2026, 18:45Smitirupa Mishra: A Practical Guide to Coagulation Pathway Assessment and Laboratory Interpretation
-
Nov 4, 2026, 15:59Alessandra Bosch: A Successful Patient Day for the Bleeding Disorders Community in Zürich
-
Nov 4, 2026, 15:47Wolfgang Miesbach: Targeting Hepatic Endothelial Cells for Lentiviral Gene Therapy in Haemophilia A
-
Nov 4, 2026, 15:20Augustina Isioma Ikusemoro: Before You Transfuse, Think PBM
-
Nov 4, 2026, 14:23Advancing Hemophilia Care Through Global Research – WFH
-
Nov 4, 2026, 14:12Jean-Jacques Kiladjian: From JAK Inhibitor-Associated Skin Cancers to Laboratory Discovery
-
Nov 4, 2026, 13:59Rita Li: ASH 2026 Abstract Achievement Award for Gut Microbiome Research
-
Nov 4, 2026, 13:38Omid Seidizadeh: Improving Access to von Willebrand Disease Diagnosis and Treatment Across Europe